Bone Therapeutics traite les premiers patients de son étude pivot de phase III évaluant JTA-004 dans l’arthrose du genou
18 mai 2020 01h00 HE
|
Bone Therapeutics SA
Communiqué de presse Traitement des premiers patients suite à la reprise des activités cliniques à Hong-Kong Approbation de l’étude de phase III évaluant JTA-004 dans cinq pays sur les sept dans...
Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
18 mai 2020 01h00 HE
|
Bone Therapeutics SA
Press Release First patients treated following resumption of clinical activities in Hong Kong JTA-004 phase III study approved in five of seven territories Gosselies, Belgium, 18 May 2020, 7am...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
06 mai 2020 16h30 HE
|
ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
05 mars 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
24 févr. 2020 16h01 HE
|
Retrophin, Inc.
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
11 févr. 2020 16h01 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
07 janv. 2020 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Oxford, UK, and Cambridge, MA, US, 7 January 2020...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
16 déc. 2019 06h00 HE
|
Axsome Therapeutics, Inc.
Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically...
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
02 déc. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
08 nov. 2019 14h10 HE
|
FibroGen, Inc
Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ Roxadustat did not increase risk...